Essential Pharma has completed the acquisition of Reminyl® oral capsules from Janssen Pharmaceutica NV, a Johnson & Johnson company.
Reminyl®, a cholinesterase inhibitor, is an...
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LX2006, Lexeo Therapeutics’ AAVrh.10hFXN-based gene therapy candidate for the treatment of...